Nasal Allergen Challenge - Reproducibility of Biomarkers and Effect of Topical Steroid Treatment
NCT ID: NCT03431961
Last Updated: 2018-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2018-03-07
2019-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nasal Allergen Challenge in Rhinitic Subjects
NCT01286129
Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge
NCT01657097
Repeat Nasal Allergen Challenge
NCT00290368
Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges*
NCT01240889
A Study of the Effects of Single Dose Corticosteroids on Response to Allergens
NCT00828061
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
0.9% normal saline administered twice daily for 14 days
Placebo
twice daily for 14 days
Intranasal Corticosteroid
Triamcinolone acetonide aqueous nasal spray at a dose of 220 mcg administered twice daily (for a total daily dose of 440 mcg) for 14 days
Triamcinolone Acetonide
220 mcg administered twice daily for 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Triamcinolone Acetonide
220 mcg administered twice daily for 14 days
Placebo
twice daily for 14 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* any medication for treatment of asthma/allergic rhinitis with the exception of infrequent beta-2 agonist.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gail Gauvreau
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gail Gauvreau
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gail M Gauvreau, PhD
Role: PRINCIPAL_INVESTIGATOR
McMaster University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardio- Respiratory Research Laboratory, Hamilton Health Sciences
Hamilton, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Bauer RN, Xie Y, Beaudin S, Wiltshire L, Wattie J, Munoz C, Alsaji N, Oliveria JP, Ju X, MacLean J, Sommer DD, Keith PK, Satia I, Cusack RP, O'Byrne PM, Sperinde G, Hokom M, Li O, Banerjee P, Chen C, Staton T, Sehmi R, Gauvreau GM. Evaluation of the reproducibility of responses to nasal allergen challenge and effects of inhaled nasal corticosteroids. Clin Exp Allergy. 2023 Nov;53(11):1187-1197. doi: 10.1111/cea.14406. Epub 2023 Oct 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DC002544/HIREB3820
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.